Streetbeat News

Stock Prices

VCNX

Vaccinex shares were halted to the upside, but the stock is currently down by 25.56%.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 2:06 pm

BTCUSD

ETHUSD

Sistine Research predicts a surge in the Trump-themed Maga Memecoin (TRUMP) in the next 90 days, driven by patterns related to Ethereum (ETH) and Bitcoin (BTC). The researcher highlights the impact of Ethereum ETFs and past trends, suggesting a potential ETH pump leading up to the election, which could also boost TRUMP.

Portfolio Pulse from Khyathi Dalal

July 31, 2024 | 2:03 pm

COP

ConocoPhillips (NYSE:COP) has outperformed the market over the past 5 years with an average annual return of 15.63%, resulting in a $1000 investment growing to $2,049.93. The company's current market capitalization is $130.51 billion.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 2:03 pm

TPHS

On July 30, 2024, Trinity Place Holdings received a notice from NYSE Regulation that trading of its common stock has been suspended and proceedings to delist the stock from NYSE American have commenced.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 2:03 pm

VRTX

Vertex Pharmaceuticals (NASDAQ:VRTX) has been analyzed by 14 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $474.86, with a high of $555.00 and a low of $376.00. Recent analyst actions include several rating raises and price target increases, reflecting positive sentiment towards the company's financial performance and product portfolio.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 2:01 pm

OUT

Outfront Media (NYSE:OUT) has been analyzed by six analysts, revealing a range of sentiments from bullish to bearish. The average 12-month price target is $17.0, with a high of $18.00 and a low of $16.00. Recent ratings include a 'Neutral' from JP Morgan, a 'Hold' from TD Cowen, and 'Outperform' from Barrington Research. The company has shown a 3.21% revenue growth rate over the last three months, but faces challenges with a net margin of -7.2%, ROE of -5.2%, and ROA of -0.53%.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 2:01 pm

HUM

Humana Inc (NYSE:HUM) reported Q2 earnings that beat expectations but issued a subpar profit outlook, causing its stock to tumble. The company posted adjusted EPS of $6.96, down from $8.94 a year ago, but above the consensus of $5.85. Revenues increased to $29.54 billion, driven by higher Medicare premiums and membership growth. Despite favorable claims development, higher inpatient admissions impacted results. Humana reaffirmed its 2024 adjusted EPS guidance of ~$16.00, below the consensus of $20.31, and expects a 2024 insurance segment benefit ratio of approximately 90%. HUM stock fell 6.32% following the announcement.

Portfolio Pulse from Vandana Singh

July 31, 2024 | 2:01 pm

ARVN

In the last three months, 6 analysts have published ratings on Arvinas (NASDAQ:ARVN), showing a range of perspectives from bullish to somewhat bullish. The average 12-month price target has decreased by 6.19% to $68.17. Analysts have adjusted their ratings and price targets in response to market conditions and company performance.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 2:00 pm

AKA

Analysts have provided mixed ratings for a.k.a. Brands Holding (NYSE:AKA) over the past quarter, with a majority being bullish. The average 12-month price target has increased to $24.5. Despite revenue challenges and below-average financial metrics, analysts maintain a positive outlook.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 2:00 pm

SPY

The USA Pending Home Sales Index for June increased to 74.3 from a revised 70.9 in the previous month, indicating a rise in pending home sales.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 2:00 pm